Navigation Links
New drugs to find the right target to fight Alzheimer's disease
Date:8/2/2013

understanding of the mechanism involved has been lacking. But with this work, the EPFL researchers were able to shed some more light on it by determining how the drug compounds affect gamma secretase and its cutting activity.

In most forms of Alzheimer's, abnormally large quantities of the long amyloid peptide 42 named like that because it contains 42 amino acids are formed. The drug compounds change the location where gamma secretase cuts the APP protein, thus producing amyloid peptide 38 instead of 42, which is shorter and does not aggregate into neurotoxic plaques.

Compared to previous therapeutic efforts, this is considerable progress. In 2010, Phase III clinical trials had to be abandoned, because the compound being tested inhibited gamma-secretase's function across the board, meaning that the enzyme was also deactivated in essential cellular differentiation processes, resulting to side-effects like in gastrointestinal bleeding and skin cancer.

"Scientists have been trying to target gamma secretase to treat Alzheimer's for over a decade," explains Patrick Fraering, senior author on the study and Merck Serono Chair of Neurosciences at EPFL. "Our work suggests that next-generation molecules, by modulating rather than inhibiting the enzyme, could have few, if any, side-effects. It is tremendously encouraging."

New insights into hereditary forms of the disease

During their investigation, the scientists also identified possible causes behind some hereditary forms of Alzheimer's disease. Early-onset Alzheimer's can appear as early as thirty years of age, with a life expectancy of only a few years. In vitro experiments and numerical simulations show that in early-onset patients, mutations in the APP protein gene modify the way by which APP is cut by the gamma-secretase enzyme. This results in overproduction of amyloid peptide 42, which then aggregates into amyloid plaques.

This research illuminates much
'/>"/>

Contact: Patrick Fraering
patrick.fraering@epfl.ch
41-795-938-785
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Alternative target for breast cancer drugs
2. Toward broad-spectrum antiviral drugs for common cold and other infections
3. Gene variants may predict who will benefit from breast cancer prevention drugs
4. New screening technique paves the way for protein drugs from bacteria
5. Soda and illegal drugs cause similar damage to teeth
6. A new strategy required in the search for Alzheimers drugs?
7. Drugs found to both prevent and treat Alzheimers disease in mice
8. Renaissance in new drugs for rare diseases
9. Renaissance in new drugs for rare diseases: Report in worlds largest scientific socity magazine
10. How do anticancer drugs work?
11. Mapping of cancer cell fuel pumps paves the way for new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... research shows some bees brace themselves against wind and turbulence ... approach comes at a steep cost, increasing aerodynamic drag and ... cutting into the bees, flight performance. The findings ... of Sciences . "Wind is a universal part of ...
... Calif. June 2 , 2009 SRI International, an ... results are now available from the Advanced Modular Incoherent ... by the National Science Foundation (NSF) that has recently ... Scientists are using the novel system to investigate ...
... "You are what you eat." Can these pithy words explain the ... Harvard University, who argues in a new book that the invention ... or the advent of tools -- is what led to the ... Us Human," is published today (June 1) by Basic Books. In ...
Cached Biology News:Trading energy for safety, bees extend legs to stay stable in wind 2SRI International announces findings from new upper atmospheric radar system for scientific research 2SRI International announces findings from new upper atmospheric radar system for scientific research 3SRI International announces findings from new upper atmospheric radar system for scientific research 4Harvard scientist says we are what we eat -- and what we cook 2
(Date:5/27/2015)... 27, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... has commenced a public offering of shares of ... its common stock and overallotment purchase rights to ... of common stock, warrants and overallotment purchase rights ...
(Date:5/27/2015)... The Academy of Model Aeronautics Foundation would ... Model Aviation Day. The third annual celebration will be August ... the model aviation hobby nation-wide and to introduce model flying ... 2,350 chartered clubs to celebrate the hobby and share it ... There will also be a local event at the AMA ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... May 27, 2015  CytomX, a biotechnology company ... today announced the appointments of Bob Goeltz ... Ladd as senior vice president and general ... financial officer of Onyx Pharmaceuticals, an Amgen subsidiary. ... and legal counsel to several leading biotech companies, ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3
... Jointly Offer "Always on," Secure Solution For Mobile ... (Nasdaq:ADCT; www.adc.com ) and Network365 announced today a ... solution that helps generate additional revenue for mobile ... and trusted m-commerce transactions between operators, banks and ...
... a year in which Wisconsins real-time economy gained time ... news stories suggests the state is becoming a place where ... the champagne corks just yet: Wisconsin still has a long ... high-wage jobs as the state lost in the three-year manufacturing ...
... began requiring applicants to pay significant user fees when ... biologics. Such user fees have long been required for ... related to devices and biologics. In theory, user fees ... at what cost? User fees impose a significant financial ...
Cached Biology Technology:ADC and Network365 Team to Offer New End-to-End Mobile Payment System 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 3Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden? 2
LEAF™ Purified anti-human/mouse/rat ICOS...
Purified anti-human CD182 (CXCR2)...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Request Info...
Biology Products: